1. Home
  2. CUE vs MGRM Comparison

CUE vs MGRM Comparison

Compare CUE & MGRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • MGRM
  • Stock Information
  • Founded
  • CUE 2014
  • MGRM 2016
  • Country
  • CUE United States
  • MGRM United States
  • Employees
  • CUE N/A
  • MGRM N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • MGRM Medical/Dental Instruments
  • Sector
  • CUE Health Care
  • MGRM Health Care
  • Exchange
  • CUE Nasdaq
  • MGRM Nasdaq
  • Market Cap
  • CUE 91.9M
  • MGRM 89.6M
  • IPO Year
  • CUE 2018
  • MGRM N/A
  • Fundamental
  • Price
  • CUE $1.49
  • MGRM $2.48
  • Analyst Decision
  • CUE Strong Buy
  • MGRM Strong Buy
  • Analyst Count
  • CUE 5
  • MGRM 1
  • Target Price
  • CUE $5.00
  • MGRM $4.00
  • AVG Volume (30 Days)
  • CUE 254.0K
  • MGRM 34.4K
  • Earning Date
  • CUE 03-10-2025
  • MGRM 03-14-2025
  • Dividend Yield
  • CUE N/A
  • MGRM N/A
  • EPS Growth
  • CUE N/A
  • MGRM N/A
  • EPS
  • CUE N/A
  • MGRM N/A
  • Revenue
  • CUE $9,532,000.00
  • MGRM $364,999.00
  • Revenue This Year
  • CUE $73.11
  • MGRM N/A
  • Revenue Next Year
  • CUE $11.02
  • MGRM N/A
  • P/E Ratio
  • CUE N/A
  • MGRM N/A
  • Revenue Growth
  • CUE 149.53
  • MGRM N/A
  • 52 Week Low
  • CUE $0.45
  • MGRM $1.53
  • 52 Week High
  • CUE $2.37
  • MGRM $4.90
  • Technical
  • Relative Strength Index (RSI)
  • CUE 58.61
  • MGRM 38.31
  • Support Level
  • CUE $1.22
  • MGRM $2.66
  • Resistance Level
  • CUE $1.50
  • MGRM $2.85
  • Average True Range (ATR)
  • CUE 0.12
  • MGRM 0.14
  • MACD
  • CUE 0.00
  • MGRM -0.04
  • Stochastic Oscillator
  • CUE 96.67
  • MGRM 15.16

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About MGRM Monogram Orthopaedics Inc.

Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.

Share on Social Networks: